Personal/family history of allergy or hypersensitivity to testosterone or related drugs
Past history of anaphylaxis or angioedema
Any major illness in the past 3 months or any clinically significant ongoing chronic medical illness (e.g., congestive heart failure, hepatitis, pancreatitis, etc.)
Presence of any clinically significant abnormal values during screening (e.g., significant abnormality of liver function test [LFT], renal (kidney) function test [RFT], etc.)
Hemoglobin <13 g/dL or hematocrit >52% during screening
Any cardiac, renal, or liver impairment; any other organ or system impairment
Asthmatic subjects with a forced expiratory volume in 1 second (FEV1) predicted <80%
History of seizure or clinically significant psychiatric disorders
Presence of disease markers for human immunodeficiency virus (HIV) 1 and/or 2, Hepatitis B and/or C (HBsAg and/or HCV) virus
History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty (“nose job”), or sinus surgery
Subjects with prior nasal fractures
Subjects with mucosal inflammatory disorders, specifically pemphigus, or Sjogren’s syndrome, rhinitis sicca
Subjects with sinus disease, specifically acute sinusitis, chronic sinusitis, or allergic fungal sinusitis
History of nasal disorders (e.g., polyposis, recurrent epistaxis [>1 nose bleed per month]), abuse of nasal decongestants, or sleep apnea
Subjects using any form of intranasal medication delivery, specifically nasal corticosteroids and oxymetazoline at the time of screening/enrolment
History of asthma and/or ongoing asthma treatment
Regular drinkers of more than 3 units of alcohol daily (1 unit = 300 mL beer, 1 glass wine = 200 mL, 1 measure spirit = 1 cL of pure alcohol), or consumption of alcohol within 48 hours prior to dosing and during the study
Subjects demonstrating a positive test for alcohol consumption (using breath alcohol analyzer) at the time of check-in during the admission periods
History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, before the start of this study
Subjects demonstrating a positive test for drugs of abuse in urine (opiates, benzodiazepines, amphetamines, tetrahydrocannabinol [THC], and cocaine) at the time of check-in during admission periods
Inaccessibility of veins in left and right arms
Receipt of any prescription drug therapy within 4 weeks of the first admission period
Prescription medication and difficulty in abstaining from over-the-counter (OTC) medication (except occasional paracetamol/aspirin) for the duration of the study
Subjects demonstrating serum PSA ≥4 ng/mL
Participation in any other research study involving an investigational new product or device (IND) or studies that required blood sampling, during the conduct of this study or 30 days prior to screening of this study (Visit 1)
Blood donation (usually 550 mL) at any time during this study, or within the 12-week period before study start
